23 June 2020: Lab/In Vitro Research
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
Xiaoqiu Wu 123BEF* , Fangfei Li 123AG** , Yongshu Li 1BF , Yuanyuan Yu 13DF , Chao Liang 13C , Baoting Zhang 4DE , Chuanzong Zhao 56B , Aiping Lu 12378AG* , Ge Zhang 123AG*DOI: 10.12659/MSM.925583
Med Sci Monit 2020; 26:e925583
Figure 4 Identify the specific aptamer targeting PD-L1 over-expressed MDA-MB-231 cells. (A) Flow cytometric assay showing the binding of XQ-P3 or RS to MDA-MB-231 PD-L1 OE and MDA-MB-231 PD-L1 KO cells. The DNA concentration is 250 nM. (B) Confocal microscopy images of XQ-P3 (250 nM) in 2 MDA-MB-231 cell lines. Scale bar=100 μm. (C) Secondary structure of XQ-P3 predicted by NUPACK. (D) The dissociation constant of XQ-P3 binding with MDA-MB-231 PD-L1 OE cells was determined by flow cytometry (n=3). RS, a random sequence served as a negative control of XQ-P3 aptamer.